Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 101 related to Glasziou: Monitoring Cholesterol Levels: Measurement Error or True Change?. (0.09 sec) 

Monitoring Cholesterol Levels: Measurement Error or True Change?

- annals.org [PDF] 
PP Glasziou, L Irwig, S Heritier, RJ Simes, A … - Annals of Internal Medicine, 2008 - Am Coll Physicians
Objective: To estimate, in patients receiving cholesterol-lowering medication,
the variation in initial response to treatment, the long- term drift from
initial response, and the detectability of long-term changes in ...
Cited by 7 - Related articles - All 5 versions

Healthcare policy implications of heterogeneity of treatment effects


MJ McLaughlin - The American Journal of Medicine, 2007 - Elsevier
Heterogeneity of treatment effects (HTE) is a phenomenon wherein the same
treatment produces different responses in different patients. Following
scientific presentations at a conference on HTE in drug therapy, a ...
Cited by 4 - Related articles - All 3 versions

[CITATION] Monitoring Cholesterol Levels: Measurement Error or True Change?


C Values
Related articles

Home| Evidence Based Therapeutics| MeReC| MeReC Bulletin Volume 19 No 3


C Activities, N Medicines, NPCT Network - MeReC Bulletin, 2009 - npc.co.uk
ICSs are safe and effective for most patients with asthma, although the risk of
systemic side effects is greater when higher doses are used. The dose of ICS
should be titrated to the lowest dose at which effective control of asthma ...
Related articles - Cached - All 2 versions

Do we know how to set decision thresholds for diabetes?


Y Ben-Haim, M Zacksenhouse, C Keren, CC … - Medical Hypotheses, 2009 - Elsevier
The diagnosis of diabetes, based on measured fasting plasma glucose level,
depends on choosing a threshold level for which the probability of failing to
detect disease (missed diagnosis), as well as the probability of falsely ...
Related articles - All 49 versions

Lipid lowering: what and when to monitor


MH Criqui, BA Golomb - The Lancet, 2008 - Elsevier
Drug treatment for dyslipidaemia is a mainstay of clinical practice in developed
countries. Monitoring of lipid-lowering treatment contributes additionally to
the already substantial cost. 1 In the randomised LIPID trial (pravastatin ...
Related articles - All 35 versions

[PDF] Do We Really Know How to Set Decision Thresholds?


Y Ben-Haim, M Zacksenhouse, C Keren, CC … - technion.ac.il
Diagnosis and treatment is a complex interaction of subjective information and
impressions, objective data, individual needs and preferences, and resource
constraints. The interpretation of quantitative information relies on ...
Related articles - View as HTML - All 5 versions

[CITATION] Last literature review for version 16.3: Wed Oct 01 00: 00: 00 GMT 2008| This topic last …


RS Rosenson, MW Freeman, DM Rind
Related articles

[CITATION] Clinical Knowledge Summaries, 2007


CKS Asthma - Accessed from http://www. cks. library. nhs. uk/asthma …
Cited by 2 - Related articles

[PDF] Trends in Medicare Carrier-Paid Laboratory Testing Services


C Hogan - Accessed at www. clinical-labs. org/documents/ …, 2008 - clinical-labs.org
The Centers for Medicare and Medicaid Services (CMS) and the Medicare Payment
Advisory Commission (MedPAC) have both cited increased use of testing as a
factor contributing to spending growth. CMS defines testing to include a ...
Cited by 2 - Related articles - View as HTML - All 2 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google